✦ LIBER ✦

Phase I study of CI-958 in children and adolescents with recurrent solid tumors

✍ Scribed by Carola A. S. Arndt; Mark D. Krailo; Wen Liu-Mares; Peter M. Anderson; Gregory H. Reaman

Publisher: John Wiley and Sons
Year: 2001
Tongue: English
Weight: 63 KB
Volume: 91
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(20010315)91:6<1166::aid-cncr1113>3.0.co;2-y

No coin nor oath required. For personal study only.

✦ Synopsis

BACKGROUND. CI-958 is a synthetic intercalating agent of a new chemical class, the benzopyranoindazoles, with promising preclinical activity. Its mechanism of action is thought to be stabilization of the cleavable complex of DNA with topoisomerase II, as well as DNA helicase blockade. It is thought to have less cardiotoxicity than the anthracyclines. Early Phase I studies in adults showed the drug to be well tolerated, making it an attractive agent to pursue in Phase I clinical trials in children.

METHODS.

Children and adolescents with recurrent solid tumors received CI-958 at an initial dose of 450 mg/m 2 over 2 hours. Dose escalation was performed in a standard fashion in cohorts of three patients until dose limiting toxicity and the maximum tolerated dose were determined.

RESULTS.

Twenty-one patients were entered on the study. The maximum tolerated dose was found to be 650 mg/m 2 . Dose limiting toxicities were Grade 4 neutropenia and Grade 4 hypotension at the dose level of 700 mg/m 2 .

CONCLUSIONS.

The maximum tolerated dose of CI-958 in children and adolescents is 650 mg/m 2 . No antitumor activity has been observed. Cancer 2001;91:1166 -9.

📜 SIMILAR VOLUMES

Phase II study of daily oral etoposide i

Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors

✍ Needle, Michael N.; Molloy, Patricia T.; Geyer, J. Russell; Herman-Liu, Alisa; B 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 315 KB 👁 2 views

Pre-clinical data and adult experience suggests that topoisomerase targeted anti-cancer agents may be highly schedule dependent, and efficacy may improve with prolonged exposure. To investigate this hypothesis, 28 children with recurrent brain and solid tumors were enrolled in a phase II study of or

Hyperthermia for the treatment of patien

Hyperthermia for the treatment of patients with malignant germ cell tumors : A Phase I/II study in ten children and adolescents with recurrent or refractory tumors

✍ Rüdiger Wessalowski; Heidi Kruck; Hildegard Pape; Thomas Kahn; Reinhart Willers; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 2 views

waves in combination with platinum-based chemotherapy in ten children and 4 Institute of Statistics, Heinrich-Heine Univeradolescents with recurrent or refractory GCTs. sity, Du ¨sseldorf, Germany. ## RESULTS. Seven of ten patients with recurrent or refractory GCTs had objective responses. Of the

A phase II study of carboplatin in child

A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the childrens cancer group

✍ Lawrence J. Ettinger; Paul S. Gaynon; Mark D. Krailo; Ning Ru; Edward S. Baum; S 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 442 KB 👁 2 views

Background. Carboplatin is an analogue of cisplatin with less nonhematologic toxicity than

A phase I study of gemcitabine and docet

A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors

✍ David P. Ryan; Thomas J. Lynch; Michael L. Grossbard; Michael V. Seiden; Charles 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 1 views

A Phase I study was initiated to determine the maximum tolerated dose of weekly gemcitabine combined with monthly, fixed-dose docetaxel. ## METHODS. Patients with metastatic solid tumors were treated with docetaxel, 60 mg/m 2 , on Day 1 every 28 days. Gemcitabine was administered on Days 1, 8, and

Phase I bioequivalency study of MitoExtr

Phase I bioequivalency study of MitoExtra and mitomycin C in patients with solid tumors

✍ Peter Kozuch; Paulo M. Hoff; Kenneth Hess; Jennifer Adams; Robert A. Newman; Fra 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 1 views

Phase I trial of subcutaneous interleuki

Phase I trial of subcutaneous interleukin-1α in children with malignant solid tumors

✍ Furman, Wayne L.; Luo, Xiaolong; Fairclough, Diane; Garrison, Leslie; Marina, Ne 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB

Interleukin-1 alpha (IL-1 alpha) is myeloprotective in a variety of animal models of cancer chemotherapy and is similarly beneficial in adults treated with carboplatin, 5-fluorouracil, and after autologous bone marrow transplantation. There are no trials of this agent in children. Our purpose was to